In comparing this year’s large ASH meeting to previous years, we support group leaders continued to see lots of myeloma interest and research. Myeloma sessions were full with some overflowing even the overflow room! Myeloma was especially exciting at last year’s ASH because it closely followed an unparalleled “November to Remember” with three new drug […]
This year’s ASH is going by quickly with our days full of activity. We IMF support group leaders began this morning with a group discussion of our days to date. We covered many of the new advancements (largely immunotherapy) and discussed new potential drugs like Selinexor®. We must remember that releasing the immune system to […]
Patients understand that improved treatment for myeloma can result in unprecedented depth of response, and myeloma treatment has changed dramatically in the last few years. Prior to 1997 when I was diagnosed, complete response (CR) was defined as a 75% reduction in M-protein. Stringent CR (sCR) did not exist because this deep level of control […]
For the last 57 years, ASH’s annual meeting has served as the world’s premier source of information and scientific exchange in all aspects of hematology. The 58th edition of this huge event for ~25,000 attendees will take place in San Diego the first week of December. Just as it has for the last ten years, […]
Diagnosed with myeloma in 1997, Jim’s advocacy work includes involvement with the National Cancer Institute’s Steering Committee, the FDA, the Alliance Cooperative Group (Myeloma and Transplant Committees), Center for International Blood and Marrow Transplant Research, Moffitt Cancer Center, Fred Hutchinson Cancer Research Center, ASCO (CancerLinQ and bisphosphonates in Myeloma Review Panel), and of course, his Central Nebraska Myeloma Support Group.
Follow Jim on Twitter
